Recursion Pharmaceuticals Profit Margin

The latest profit margin for RXRX is -945.92% as of June 2026. That compares with -1007.07% in the prior-year period — up 6.1% year over year. That is below the Healthcare sector average of 13.89%. Investors often review this figure alongside Recursion Pharmaceuticals's historical trend and sector peers before judging valuation or financial health.

Over the past year, RXRX's profit margin moved from -1007.07% to -945.92% — a 6.1% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Recursion Pharmaceuticals's valuation or profitability profile.

Against Healthcare companies, RXRX currently prints -945.92% for profit margin, while the sector average sits near 13.89%. That is roughly 6908.6% below the sector mean. Large gaps often invite a closer look at Recursion Pharmaceuticals's growth, margins, and balance sheet.

Profit Margin shows how effectively Recursion Pharmaceuticals converts resources into returns. At -945.92%, RXRX may look efficient or underperforming depending on peer benchmarks and trend direction. That compares with -1007.07% in the prior-year period — up 6.1% year over year. Pair the percentage with revenue growth and leverage for a fuller health check.

After noting RXRX's profit margin (-945.92%), review year-over-year change from -1007.07%, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.